Our previous study demonstrated that EFHD2 promotes epithelial-to-mesenchymal transition (EMT) in NSCLC cells and is significantly associated with postsurgical recurrence in patients with stage I NSCLC [10], suggesting EFHD2 as a molecular marker for predicting recurrence. The gene discussed is EFHD2; the disease is non-small cell lung carcinoma.